Acquisition potential WuXi AppTec’s acquisition of CRELUX in 2016 and CRELUX’s role as a global structure based drug discovery provider suggest a potential upsell opportunity within WuXi’s integrated platform to further enhance collaboration across crystallography, biophysics and fragment screening for client programs.

Integrated services Leverage CRELUX as a bridge to offer end-to-end discovery solutions that combine X-ray crystallography, protein supply, biophysical analysis and fragment screening with WuXi AppTec’s broader service portfolio to existing clients seeking faster, more efficient hit to lead progress.

Mid market focus With a mid-sized footprint (51-200 employees) and revenue in the lower tens of millions, CRELUX represents a profitable entry point for expanding service penetration into small to mid-size biotech and pharma companies seeking boutique, high-value structure-based discovery support.

Global capability Position CRELUX as a gateway to international collaborations, highlighting their global structure-based capabilities and Graefelfing, Germany base to attract European clients seeking proximity to EU regulatory and collaboration ecosystems.

Growth through tech Emphasize CRELUX’s tech-enabled workflow and WuXi-backed scale to win clients prioritizing advanced protein science, fragment screening and crystallography, leveraging the combined tech stack and R&D capabilities for accelerated program timelines.